Gary Jay Sternberg
Chief Tech/Sci/R&D Officer at AERIE PHARMACEUTICALS, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Benjamin Yerxa | M | 58 |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | - |
David Endicott | M | 58 | 2 years | |
Frances Martin | M | - |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | - |
Tad Heitmann | M | - | 6 years | |
Leon Sergio Duplan Fraustro | M | 57 | 2 years | |
Timothy Stonesifer | M | 56 | 2 years | |
Marvin J. Garrett | M | 73 | 10 years | |
Carolyn McAuliffe | F | - | 3 years | |
Brian Gilger | M | - |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | - |
Matthew Hirsch | M | - |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | - |
Ann Keevans | F | - | - | |
David Biddell | M | - | - | |
Evan Hockman | M | - | - | |
Vincent Santucci | M | - | - | |
Kenji Aso | M | - | - | |
Damien Monaghan | M | - | - | |
Wanda Francies | F | - | - | |
Jonathan Balch | M | - | 2 years | |
Leon J. Atencia | M | - | 3 years | |
Richard Gaster | M | 40 |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | 4 years |
Andrew Allen | M | - | - | |
Gregory Jones | M | - | 4 years | |
Gianluca Corbinelli | M | - | - | |
Ian Bell | M | 54 | 2 years | |
John Wagner | M | - |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | - |
Gerry McKenzie | M | - | - | |
Craig R. Skenes | M | - | 10 years | |
Royce Bedward | M | 58 | 2 years | |
Daniel Curran | M | 57 |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | 5 years |
Michelle Senchyna | M | - | 4 years | |
Nanna Liebach Lüneborg | M | 49 |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | - |
Mitchell de Long | M | - | 19 years | |
Martin Edwards | M | 68 |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | - |
Tom Hudnall | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Benjamin McGraw | M | 75 | 8 years | |
Stephen Allen Hurly | M | 56 | 2 years | |
Wendy Dixon | M | 68 | 6 years | |
Jay Duker | M | 66 | 8 years | |
Casey C. Kopczynski | M | 62 | 17 years | |
Cary Pfeffer | M | 61 | 7 years | |
Rajkumar Kannan | M | 61 | 1 years | |
Gregory P. Adams | M | - | - | |
John W. LaRocca | M | 59 | 4 years | |
Michael du Toit | M | 71 | 7 years | |
Barry Gertz | M | 72 | - | |
Peter John McDonnell | M | 66 | 2 years | |
Leah Monteiro | F | - | - | |
Cameron Wheeler | M | 45 | - | |
Julie McHugh | F | 59 | 7 years | |
David Berry | M | 47 | 7 years | |
Richard Croarkin | M | 69 | 7 years | |
Gerald D. Cagle | M | 79 | 9 years | |
David Gryska | M | 68 | 4 years | |
Noubar Afeyan | M | 60 | 6 years | |
Mark Levin | M | 73 | 6 years | |
Arthur P. DeCillis | M | 68 | 1 years | |
Eric S. Furfine | M | 64 | 6 years | |
Glen C. MacDonald | M | 66 | - | |
Leslie Lewis Dan | M | 94 | 3 years | |
Karen L. Tubridy | M | 61 | 3 years | |
Greg Zarbis-Papastoitsis | M | - | 6 years | |
Michael H. Goldstein | M | 57 | 2 years | |
Kathleen McGinley | F | 74 | 7 years | |
Gregory Perry | M | 63 | 1 years | |
Peter F. Lang | M | 52 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 65 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gary Jay Sternberg
- Personal Network